Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115816) titled 'A randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of oral Lactobacillus reuteri in treating skin barrier function impairment caused by obesity' on Dec. 31, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shenzhen People's Hospital
Condition:
Non-infectious skin diseases
Intervention:
The oral trial group of Lactobacillus reuteri:Take 1x10^11 CFU of Lactobacillus reuteri orally once a day for one month.
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-01-05
Target Sample Size: The oral trial group...